Redcare Pharmacy Stock Price

RDC Community Fair Values

• AN

  

  AnalystLowTarget

  Consensus Narrative from 9 Analysts

  Germany eRx Delays Will Pressure The Sector Yet Spark Recovery

  Key Takeaways Heavy reliance on electronic prescription adoption and regulatory trends poses significant risks to growth and revenue predictability. Intensifying competition, persistent offline loyalty, and regulatory scrutiny threaten market share, margin expansion, and sustainable digital penetration.

  €94.39

  FV

  4.3% overvalued intrinsic discount

  18.47%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  1users have followed this narrative

  12 days ago author updated this narrative
• AN

  

  AnalystConsensusTarget

  Consensus Narrative from 9 Analysts

  Germany e-Rx Adoption And European Expansion Will Unlock New Opportunities

  Key Takeaways Strategic expansion and marketing efforts, including e-Rx adoption, enhance market access, customer acquisition, and engagement, potentially boosting revenue growth and market leadership. Improved logistics and marketplace operations drive better margins and profitability, with a growing customer base and larger order sizes fueling future revenue and earnings.

  €163.67

  FV

  39.8% undervalued intrinsic discount

  18.90%

  Revenue growth p.a.

  1users have liked this narrative

  0users have commented on this narrative

  9users have followed this narrative

  5 days ago author updated this narrative
• AN

  

  AnalystHighTarget

  Consensus Narrative from 9 Analysts

  Digital Channels And Aging Trends Will Reshape European Healthcare

  Key Takeaways Accelerated digital adoption and personalized app-based engagement could enable Redcare Pharmacy to outperform revenue and margin expectations, driving structural cost efficiencies and higher profitability. Expanding its marketplace and digital health services positions Redcare to dominate the European health platform space, benefiting from persistent demand and untapped high-margin opportunities.

  €214.00

  FV

  54.0% undervalued intrinsic discount

  27.37%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  12 days ago author updated this narrative